Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435316 | 1.00 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1949536 | 0.87 | MAPT (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL5427451 | 0.86 | HTR2B (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5427024 | 0.82 | HSD17B3 (0.54) | MAOBMAPTALDH1A1CYP2D6MAOA | |
| SCHEMBL404591 | 0.80 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL404592 | 0.80 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Juarezic Acid SCHEMBL28990093 | 0.78 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5431012 | 0.78 | HDAC2 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5436185 | 0.78 | HSD11B1 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Juarezic Acid SCHEMBL144681 | 0.75 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HDAC3 262/4885HDAC4 238/4885HDAC1 336/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HDAC3 262/4885HDAC4 238/4885HDAC1 336/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HDAC3 409/4885HDAC4 366/4885HDAC1 400/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | HDAC3 262/4885HDAC4 238/4885HDAC1 336/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HDAC3 293/4885HDAC4 230/4885HDAC1 269/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HDAC3 293/4885HDAC4 230/4885HDAC1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.